Raltegravir, an Important New Drug Option

In a head-to-head comparison of three drugs presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) on Wednesday, the integrase inhibitor (II) raltegravir (Isentress) proved to be superior, in terms of the overall likelihood of treatment failure, when compared to the two ritonavir-boosted protease inhibitors (PIs) atazanavir (Reyataz) and darunavir (Prezista). All three drugs were […]

Raltegravir Can Lead to Central Nervous System (CNS) Symptoms in Some People

Approximately 10% of patients taking the antiretroviral drug raltegravir (Isentress), an Integrase Inhibitor,  develop central nervous system (CNS) side-effects. The development of CNS side-effects was associated with the co-administration of tenofovir (Viread, also found in the co-formulations Truvada, Atripla and Eviplera) and of proton pump inhibitors (drugs used to reduce gastric acid). The investigators believe these drugs interact with […]